Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.
Dayan CM, Lecumberri B, Muller I, Ganesananthan S, Hunter SF, Selmaj KW, Hartung HP, Havrdova EK, LaGanke CC, Ziemssen T, Van Wijmeersch B, Meuth SG, Margolin DH, Poole EM, Baker DP, Senior PA. Dayan CM, et al. Among authors: poole em. Mult Scler J Exp Transl Clin. 2023 Jan 3;9(1):20552173221142741. doi: 10.1177/20552173221142741. eCollection 2023 Jan-Mar. Mult Scler J Exp Transl Clin. 2023. PMID: 36619856 Free PMC article.
Predictors of residual disease after debulking surgery in advanced stage ovarian cancer.
Abbas-Aghababazadeh F, Sasamoto N, Townsend MK, Huang T, Terry KL, Vitonis AF, Elias KM, Poole EM, Hecht JL, Tworoger SS, Fridley BL. Abbas-Aghababazadeh F, et al. Among authors: poole em. Front Oncol. 2023 Jan 24;13:1090092. doi: 10.3389/fonc.2023.1090092. eCollection 2023. Front Oncol. 2023. PMID: 36761962 Free PMC article.
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Schjesvold F, Bringhen S, G Richardson P, Perrot A, Leleu X, Moreau P, A Dimopoulos M, Hulin C, Tekle C, Foster MC, Poole EM, van de Velde H, Facon T. Schjesvold F, et al. Among authors: poole em. Am J Hematol. 2021 Nov 1;96(11):E423-E427. doi: 10.1002/ajh.26319. Epub 2021 Sep 23. Am J Hematol. 2021. PMID: 34383345 Free article. Clinical Trial. No abstract available.
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Sternberg CN, Castellano D, de Bono J, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, de Wit R. Sternberg CN, et al. Among authors: poole em. Eur Urol. 2021 Oct;80(4):497-506. doi: 10.1016/j.eururo.2021.06.021. Epub 2021 Jul 15. Eur Urol. 2021. PMID: 34274136 Clinical Trial.
An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Thiery-Vuillemin A, Fizazi K, Sartor O, Oudard S, Bury D, Thangavelu K, Ozatilgan A, Poole EM, Eisenberger M, de Bono J. Thiery-Vuillemin A, et al. Among authors: poole em. ESMO Open. 2021 Apr;6(2):100089. doi: 10.1016/j.esmoop.2021.100089. Epub 2021 Mar 16. ESMO Open. 2021. PMID: 33740734 Free PMC article.
160 results